Результаты поиска

Review of Adoptive Cellular Therapies for the Treatment of Sarcoma.

Sarcomas are a heterogeneous group of malignancies with limited therapeutic options, particularly in the metastatic setting. Adoptive cellular therapies (ACTs), including tumor-infiltrating lymphocyte (TIL) therapy, chimeric antigen receptor (CAR) T-cell therapy, and T-cell receptor (TCR) gene-modified T-cell therapy, offer promising novel approaches for these refractory tumors. TIL-based therapy has demonstrated early efficacy in melanoma and myeloma, with ongoing trials exploring its role in sarcoma. CAR T-cell strategies targeting HER2, GD2, and B7-H3 antigens are in development, though cha

Совпадение в полном тексте источника
… In the pivotal SPEARHEAD trial, 52 patients with metastatic or unresectable SS or MRCLS who had previously received treatment with an anthracycline or ifosfamide-containing regimen were given afami-cel following a regimen of lymphodepleting fludarabine and cyclophosphamide [ 29 ]. … D’Angelo et al. later reported on a pilot study of NY-ESO-1 engineered TCRs (termed SPEAR T-cells) for the treatment of histologically confirmed unresectable, or metastatic, progressive, persistent, or recurrent SS previously treated with ifosfamide or anthracycline-containing systemic chemotherapy [ …

An Exploratory Research to Evaluate the 30 Most Common Pulmonary Embolism Drugs in the Food and Drug Administration Adverse Event Reporting System.

BackgroundsPulmonary embolism (PE) is a common disease and a common cause of death. However, it is currently unclear which clinically common drugs can lead to PE.MethodsWe collected, organized, and analyzed reports from the first quarter of 2018 to the fourth quarter of 2022. We performed disproportionality analysis algorithms to calculate reporting odds ratio (ROR), which could quantify the signal values of different adverse events (AEs).ResultsWe have screened a total of 3091 drugs, with AE containing "PE" and calculated the ROR signal values of the top 30 drugs reported and ranked them. TES

Совпадение в полном тексте источника
… Lynch R., Cassaday R., Smith S., et al., “Dose‐Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide for Second‐Line Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma: A Single Centre, Phase 1/2 Study,” Lancet Haematology 8, no. 8 (2021): e562–e571. 50. …

Intensive Care Outcomes of Patients after High Dose Chemotherapy and Subsequent Autologous Stem Cell Transplantation: A Retrospective, Single Centre Analysis.

High dose chemotherapy (HDT) followed by autologous peripheral blood stem cell transplantation (ASCT) is standard of care including a curative treatment option for several cancers. While much is known about the management of patients with allogenic SCT at the intensive care unit (ICU), data regarding incidence, clinical impact, and outcome of critical illness following ASCT are less reported. This study included 256 patients with different cancer entities. Median age was 56 years (interquartile ranges (IQR): 45-64), and 67% were male. One-year survival was 89%; 15 patients (6%) required treatm

Совпадение в полном тексте источника
… (7) | 2 (13) | 1 (3) Hodgkin-Lymphoma | 8 (3) | 0 (0) | 1 (3) Miscellaneous | 11 (4) | 3 (20) | 2 (6) The main high dose chemotherapy protocols included melphalan ( n = 125), high dose carmustine/etoposide/cytarabine/melphalan (BEAM; n = 54), carboplatin/etoposide (CE; n = 41), cisplatin/etoposide/ifosfamide …

Keyword Index for Volume 110

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… HPVE7 1034 HSF1 71 Hsp 90 71 human papillomavirus 489, 1587, 2369, 2804 Human teratocarcinoma stem cells 2131 humane end points 928 hyperglycaemia 2361 hypermethylation 2874 hypermutation 2615 hypertension 797 hypofractionation 2217 hypoxia 172, 715, 935, 1014, 2865 ICAM-1 1801 ID-1 1298 ifosfamide …

ZD6474--clinical experience to date.

ZD6474 selectively targets two key pathways in tumour growth by inhibiting vascular endothelial growth factor (VEGF)-dependent tumour angiogenesis and epidermal growth factor (EGF)-dependent tumour cell proliferation and survival. Phase I clinical evaluation has shown ZD6474 to be generally well tolerated, with a pharmacokinetic profile appropriate for once-daily oral dosing. Phase II evaluation of ZD6474 at doses of 100-300 mg is ongoing in a range of patient types in single and combination regimens. These include three randomised studies of patients with non-small-cell lung cancer. In one of

Совпадение в полном тексте источника
… J Natl Cancer Inst 89: 881–886 Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, Moore M, Gandara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F, Hammershaimb L (2000) Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced …

Baseline platelet-to-lymphocyte ratio is associated with severe immune effector cell-associated toxicities in diffuse large B-cell lymphoma patients receiving anti-CD19 CAR T-cell therapy.

INTRODUCTION: Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy can induce durable remissions in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); however, severe immune effector cell-associated adverse events, including cytokine release syndrome (CRS) and neurotoxicity, remain major clinical challenges. We investigated whether the platelet-to-lymphocyte ratio (PLR) could serve as a predictive biomarker for severe toxicities. METHODS: In this retrospective study, 15 patients with relapsed or refractory DLBCL treated with tisagenlecleucel were analyzed. PLR was

Совпадение в полном тексте источника
… Among the 12 patients who received systemic chemotherapy as bridging therapy, 9 were treated with polatuzumab vedotin plus bendamustine and rituximab (pola-BR), 2 with bendamustine and rituximab (BR), and 1 with ifosfamide, carboplatin, and etoposide (ICE) ( Supplementary Table 1 ). …

Secondary Malignancies Following CAR T-Cell Therapy for B-Cell Malignancies: A Retrospective Analysis.

IntroductionChimeric antigen receptor T-cell (CART) therapy has shown clinical efficacy in relapsed and refractory large B-cell malignancies. There is emerging data on the long-term complications including risk of secondary malignancies. We aimed to describe the incidence and characteristics of secondary malignancies following CART therapy.MethodsWe performed a single-center retrospective analysis of a prospectively collected cohort of 87 patients who received CART therapy for relapsed/refractory B-cell malignancies between January 2020 and August 2023.ResultsSeven patients (8.0%) developed a

Совпадение в полном тексте источника
… large B‐cell lymphoma, PMBCL, primary mediastinal B‐cell lymphoma; tFL, transformed follicular lymphoma; BR, bendamustine, rituximab; R‐CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone; GDP, gemcitabine, cisplatin, dexamethasone; CEP, cyclophosphamide, etoposide, prednisone; ICE, ifosfamide …

Prolonged infusion time of cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) as a mobilization regimen may improve mobilization efficiency in newly diagnosed multiple myeloma patients: a single center experience.

ObjectivesThis study aimed to clarify the effectiveness and safety of two different infusion durations of cyclophosphamide (CTX) plus granulocyte colony-stimulating factor (G-CSF) for peripheral blood stem cell mobilization in patients with newly diagnosed multiple myeloma (NDMM).MethodsOne hundred and fifty-six consecutive NDMM patients receiving CTX plus G-CSF mobilization and autologous stem cell transplantation during the period of September 2008 to May 2020 were selected for retrospective analysis. According to differences in prolonged infusion time of CTX, they were divided into a 24-h g

Совпадение в полном тексте источника
… Therapeutic effects of single-push or fractionated injections or continuous infusion of oxazaphosphorines (cyclophosphamide, ifosfamide, ASTA Z 7557). Cancer. 1984;54(S1):1193–1203. doi: 10.1002/1097-0142(19840915)54:1+<1193::AID-CNCR2820541317>3.0.CO;2-Z. 40. …

Multicenter phase 2 study of romidepsin plus lenalidomide for previously untreated peripheral T-cell lymphoma.

Peripheral T-cell lymphomas (PTCLs) are associated with poor prognosis when treated with cytotoxic chemotherapy. We report the findings of a phase 2 study evaluating a chemotherapy-free combination of romidepsin plus lenalidomide as initial treatment for patients with PTCL who were aged >60 years or noncandidates for chemotherapy. Treatment was initiated with romidepsin 10 mg/m2 IV on days 1, 8, and 15 and lenalidomide 25 mg taken orally from days 1 to 21 of 28-day cycle for up to 1 year. The primary objective was overall response rate (ORR). Secondary objectives included safety and survival.

Совпадение в полном тексте источника
… Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or natural-killer/T-cell lymphoma. Haematologica. 2021;106(12):3170–3175. doi: 10.3324/haematol.2020.251454. 20. …

Incidence of Arrhythmias and Their Prognostic Value in Patients With Multiple Myeloma.

Background: Arrhythmias are common cardiovascular complications in multiple myeloma (MM) patients and are related to a poor prognosis. Objective: This study aimed to assess the burden of arrhythmias and their prognostic value in patients with MM. Methods: This was a retrospective study of patients with MM between January 2015 and April 2020 at the First Affiliated Hospital of Xi'an Jiaotong University. The incidence of arrhythmia and associated risk factors were evaluated. The relationship between the type of arrhythmia and survival was analyzed. Results: A total of 319 patients with MM were i

Совпадение в полном тексте источника
… . $ Included cyclophosphamide and ifosfamide . …

Risk factors associated with progressive increases in serum creatinine concentrations in cats with cancer receiving doxorubicin.

BackgroundAzotemia occurs in cats administered doxorubicin, but risk factors have not been explored.ObjectiveTo determine incidence of progressive increases in serum creatinine concentration in cats with cancer receiving doxorubicin in single or multiagent chemotherapy protocols and associated risk factors.AnimalsSeventy cats with cancer receiving doxorubicin.MethodsA retrospective study (2007-2017) of cats with indices of kidney function recorded before and after doxorubicin administration was reviewed. Cats diagnosed with kidney injury because of known etiologies other than possible doxorubi

Совпадение в полном тексте источника
… bodyweight or body surface area became azotemic, though there was no difference with regard to BUN and serum creatinine concentrations between groups. 9 In humans, doxorubicin is not associated with nephrotoxicosis, however, other chemotherapeutic agents, including cisplatin, mitomycin C, gemcitabine and ifosfamide …

An Update in Drug-Induced Thrombotic Microangiopathy.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Ulas A Silay K Akinci S Akinci MB Sendur MA Dede DS Thrombotic thrombocytopenic purpura following salvage chemotherapy with paclitaxel, ifosfamide and cisplatin in a patient with a refractory germ cell tumor: a case report and review of the literature . …

Histone Deacetylase Inhibitors as a Therapeutic Strategy to Eliminate Neoplastic "Stromal" Cells from Giant Cell Tumors of Bone.

The neoplastic "stromal" cells in giant cell tumor of bone (GCTB) harbor a mutation in the H3F3A gene, which causes alterations in the epigenome. Current systemic targeted therapies, such as denosumab, do not affect the neoplastic cells, resulting in relapse upon treatment discontinuation. Therefore, this study examined whether targeting the epigenome could eliminate the neoplastic cells from GCTB. We established four novel cell lines of neoplastic "stromal" cells that expressed the H3F3A p.G34W mutation. These cell lines were used to perform an epigenetics compound screen (n = 128), which ide

Совпадение в полном тексте источника
… Lenvatinib with Etoposide plus Ifosfamide in Patients with Refractory or Relapsed Osteosarcoma (ITCC-050): A Multicentre, Open-Label, Multicohort, Phase 1/2 Study Lancet Oncol. 2021 22 1312 1321 10.1016/S1470-2045(21)00387-9 34416158 …

Antiemetic Strategies in Patients Who Undergo Hematopoietic Stem Cell Transplantation.

Hematopoietic stem cell transplantation (HSCT) is an integral part of the treatment strategy in patients with a hematological disorder. Chemotherapy-induced nausea and vomiting (CINV) is still an issue in patients who undergo HSCT. While several guidelines for the antiemetic therapy against CINV have been published, there is no detailed information about appropriate antiemetic drugs for each conditioning regimen in HSCT. Various studies reported that the triplet of 5-HT3RA, NK1RA, and dexamethasone appears useful in HSCT. However, each antiemetic has unique adverse effects or interactions with

Совпадение в полном тексте источника
… The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination. Bone Marrow Transplant. 2011;46(6):784–789. doi: 10.1038/bmt.2010.205. 52. …

Real-World Characteristics, Treatment Patterns, Health Care Resource Use, and Costs of Patients with Diffuse Large B-Cell Lymphoma in the U.S.

BACKGROUND: Diffuse large B-cell lymphoma (DLBCL) represents the most common subtype of non-Hodgkin lymphoma in the U.S., but current real-world data are limited. This study was conducted to describe real-world characteristics, treatment patterns, health care resource utilization (HRU), and health care costs of patients with treated DLBCL in the U.S. MATERIALS AND METHODS: A retrospective study was conducted using the Optum Clinformatics Data Mart database (January 2013 to March 2018). Patients with an International Classification of Diseases, Tenth Revision, Clinical Modification diagnosis f

Совпадение в полном тексте источника
… Abbreviations: 1L, first line; 2L, second line; 3L, third line; 4L, fourth line; BR, bendamustine plus rituximab; R‐CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; R‐ICE, rituximab plus ifosfamide, carboplatin, and etoposide phosphate. …

A Comparative Oncology Drug Discovery Pipeline to Identify and Validate New Treatments for Osteosarcoma.

BackgroundOsteosarcoma is a rare but aggressive bone cancer that occurs primarily in children. Like other rare cancers, treatment advances for osteosarcoma have stagnated, with little improvement in survival for the past several decades. Developing new treatments has been hampered by extensive genomic heterogeneity and limited access to patient samples to study the biology of this complex disease.MethodsTo overcome these barriers, we combined the power of comparative oncology with patient-derived models of cancer and high-throughput chemical screens in a cross-species drug discovery pipeline.R

Совпадение в полном тексте источника
… Neoadjuvant Chemotherapy With Methotrexate, Cisplatin, and Doxorubicin With or Without Ifosfamide in Nonmetastatic Osteosarcoma of the Extremity: An Italian Sarcoma Group Trial ISG/OS-1 J. Clin. Oncol. 2012 30 2112 2118 10.1200/JCO.2011.38.4420 22564997 46. Taran S.J. Taran R. Malipatil N.B. …

Acute Kidney Injury in Oncology Patients.

With rapid progress in cancer diagnosis and treatment in the last two decades, outcomes in oncological patients have improved significantly. However, the incidence of acute kidney injury (AKI) in this population has also increased significantly. AKI complicates many aspects of patients' care and adversely affects their prognoses; thus, accurately diagnosing the risk factors for AKI ensures appropriate management. AKI may be caused by pre-renal, intrinsic renal, and post-renal reasons, as well as for combined reasons. This review summarizes the potential etiologies of AKI according to the three

Совпадение в полном тексте источника
… Conventional cancer drugs such as platinum compounds, ifosfamide, pemetrexed, and methotrexate, as well as targeted agents such as TKIs, anaplastic lymphoma kinase inhibitors, and BRAF gene inhibitors induce ATN. …

Bisphosphonate conjugation for bone specific drug targeting.

Bones provide essential functions and are sites of unique biochemistry and specialized cells, but can also be sites of disease. The treatment of bone disorders and neoplasia has presented difficulties in the past, and improved delivery of drugs to bone remains an important goal for achieving effective treatments. Drug targeting strategies have improved drug localization to bone by taking advantage of the high mineral concentration unique to the bone hydroxyapatite matrix, as well as tissue-specific cell types. The bisphosphonate molecule class binds specifically to hydroxyapatite and inhibits

Совпадение в полном тексте источника
… In a rat OS model, ZOL treatment reduced primary tumor size and bone lysis, and combination with ifosfamide was more effective in preventing tumor recurrence and improving tissue repair ( Heymann et al., 2005 ). … Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma Bone 37 1 2005 74 86 15894525 10.1016/j.bone.2005.02.020 Hirabayashi H. Fujisaki J. …

Epigenetic regulation in hematopoiesis and its implications in the targeted therapy of hematologic malignancies.

Hematologic malignancies are one of the most common cancers, and the incidence has been rising in recent decades. The clinical and molecular features of hematologic malignancies are highly heterogenous, and some hematologic malignancies are incurable, challenging the treatment, and prognosis of the patients. However, hematopoiesis and oncogenesis of hematologic malignancies are profoundly affected by epigenetic regulation. Studies have found that methylation-related mutations, abnormal methylation profiles of DNA, and abnormal histone deacetylase expression are recurrent in leukemia and lympho

The Use of Extracorporeal Organ Support Therapies for Acute Kidney Injury in Cancer Patients.

Acute kidney injury (AKI) is a frequent and serious complication in patients with cancer, associated not only with increased morbidity and mortality, but also with the interruption or modification of anticancer therapy. In critically ill patients with cancer, AKI arises from a complex interplay of cancer-related, treatment-related, and patient-related factors, with many patients requiring renal replacement therapy (RRT) and admission to the intensive care unit (ICU). This narrative review summarizes the etiology of AKI in patients with cancer and discusses the role of extracorporeal organ supp

Совпадение в полном тексте источника
… Delayed rhabdomyolysis with paclitaxel, ifosfamide, carboplatin, and etoposide regimen: A case report J. Med. Case Rep. 2017 11 100 10.1186/s13256-017-1272-9 28395668 PMC5387351 59. Costantini A. Moletta L. Pierobon E.S. Serafini S. Valmasoni M. Sperti C. …